Organogenesis Holdings Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Accelerated filer
State of Incorporation DE
Business Address 85 DAN ROAD, CANTON, MA, 02021
Mailing Address 85 DAN ROAD, CANTON, MA, 02021
Phone 781-575-0775
Fiscal Year End 1231
EIN 000000000
Financial Overview
FY2024 FY
$482.04M
Revenue
$15.53M
Net Income
$278.66M
Stockholders' Equity
$135.57M
Cash & Equivalents
$0.12
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | February 12, 2026 | View on SEC |
| 8-K Current report of material events | December 29, 2025 | View on SEC |
| 4 Insider stock transaction report | December 18, 2025 | View on SEC |
| 4 Insider stock transaction report | November 26, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 6, 2025 | View on SEC |
| 8-K Current report of material events | November 6, 2025 | View on SEC |
| 4 Insider stock transaction report | November 3, 2025 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | November 3, 2025 | View on SEC |
| 8-K Current report of material events | September 25, 2025 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | August 14, 2025 | View on SEC |
Insider Trading
STRONG SELL 1 insiders
4 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.